Posttransplantation Lymphoproliferative Disorder in Lung Transplant Recipients
Authors:
- Eli MuchtarEMEli Muchtar
- Mordechai R. KramerMKMordechai R. Kramer
- Liat VidalLVLiat Vidal
- Ron RamRRRon Ram
- Ronit GurionRGRonit Gurion
- Yivgenia RosenblatYRYivgenia Rosenblat
- Ilana BakalIBIlana Bakal
- Ofer ShpilbergOSOfer Shpilberg
- 15 October 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 96 (7) , 657-663
Abstract
Posttransplantation lymphoproliferative disorder (PTLD) is a well-recognized complication after solid-organ transplantation. Historically, most cases of PTLD among lung transplant recipients occurred within the first year from transplantation and were associated with Epstein-Barr virus (EBV) infection. However, there are increasing reports on a late-onset form of PTLD. We reviewed all charts of patients undergoing either lung or heart-lung transplantation in a tertiary transplantation center between the years 1997 and 2012 and compared clinical and pathologic parameters between early- and late-onset PTLD. Ten patients with PTLD were identified. Median (range) time from transplantation to PTLD diagnosis was 41 (4-128) months. Three patients developed early PTLD. All were pretransplantation EBV seronegative and asymptomatic when diagnosed during surveillance chest imaging. In contrast, the seven patients with late-onset PTLD were all EBV seropositive before transplantation and were symptomatic at diagnosis. Although early-onset PTLD uniformly involved the transplanted lung, this was relatively rare in late-onset PTLD (3 of 3 vs. 1 of 7). All patients were initially treated with reduction of immunosuppression, with at least one additional treatment modality used, mainly chemoimmunotherapy. Eight patients attained complete remission. With a median follow-up of 17 months, 8 patients died, mainly from treatment-related causes rather than disease progression. Our cohort of lung transplant recipients demonstrates a trend of late-onset PTLD with the majority of patients who died of treatment-related causes rather than disease progression. Therefore, substantial efforts should be focused on treatment-related mortality reduction.Keywords
This publication has 27 references indexed in Scilit:
- Post‐transplant lymphoproliferative disorders in lung transplant recipients: 20‐yr experience at the University of MinnesotaClinical Transplantation, 2010
- Post‐transplant lymphoproliferative disease in pediatric lung transplant recipients: Recent advances in monitoringPediatric Transplantation, 2009
- B-cell Posttransplant Lymphoproliferative Disorders in Heart and/or Lungs Recipients: Clinical and Molecular-Histogenetic Study of 17 Cases from a Single InstitutionTransplantation, 2006
- Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantationCritical Reviews in Oncology/Hematology, 2005
- Early onset post‐transplant lymphoproliferative disease is associated with allograft localizationClinical Transplantation, 2005
- Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2004
- Posttransplant Lymphoproliferative DisorderChest, 2003
- Posttransplant Lymphoproliferative Disorders in Lung Transplant Patients: The Cleveland Clinic ExperienceLaboratory Investigation, 2002
- EPSTEIN-BARR VIRUS-NEGATIVE LYMPHOPROLIFERATIVE DISORDERS IN LONG-TERM SURVIVORS AFTER HEART, KIDNEY, AND LIVER TRANSPLANT1Transplantation, 2000
- Post-Transplantation Lymphoproliferative Disorder in the Epstein-Barr Virus-Naïve Lung Transplant RecipientAmerican Journal of Respiratory and Critical Care Medicine, 1996